Back to results
US 2023/0053688 A1Published application
Methods to alter latency in ebv+ malignancies
AssigneeCornell University
InventorsLisa G. Roth, Ethel Cesarman
Life of this patent
Estimating the term…
Abstract
Methods of altering viral latency, sensitizing EBV+ tumors, or modulating viral immunogenicity, are provided.
Claims24
A method to convert EBV latency I tumors in a mammal to EBV latency II/III tumors or to sensitize EBV+ tumors in a mammal to T-cell mediated killing, comprising:
- administering to the mammal a composition comprising an effective amount of one or more hypomethylating agents or DNA methyl transferase inhibitors.
(canceled)
A method to modulate viral immunogenicity in a mammal having EBV+ lymphoma, comprising:
- administering to the mammal a composition comprising an effective amount of one or more hypomethylating agents or DNA methyl transferase inhibitors.
(canceled)
The method of 15 wherein the immunotherapeutic is orally administered.
An in vitro method to detect an agent that converts EBV latency I tumor cells to EBV latency II/III tumors, comprising:
- contacting EBV latency I tumor cells with one or more agents;
- and
- determining whether the one or more agents convert the EBV latency I tumor cells to EBV latency II/II tumor cells.
(canceled)
24-26. (canceled)
Dependencies are inferred from the claim text.